Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.

MLA

Bower, Julie K., et al. “Real-World Safety and Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: Interim Results of a Long-Term Registry-Based Study.” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, vol. 22, no. 4, July 2023, pp. 730–37. EBSCOhost, https://doi.org/10.1016/j.jcf.2023.03.002.

APA

Bower, J. K., Volkova, N., Ahluwalia, N., Sahota, G., Xuan, F., Chin, A., Weinstock, T. G., Ostrenga, J., & Elbert, A. (2023). Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 22(4), 730–737. https://doi.org/10.1016/j.jcf.2023.03.002

Chicago

Bower, Julie K, Nataliya Volkova, Neil Ahluwalia, Gurvaneet Sahota, Fengjuan Xuan, Anna Chin, Tanya G Weinstock, Josh Ostrenga, and Alexander Elbert. 2023. “Real-World Safety and Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: Interim Results of a Long-Term Registry-Based Study.” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society 22 (4): 730–37. doi:10.1016/j.jcf.2023.03.002.